Visual analysis of tyrosine kinase inhibitors in HER2 positive breast cancer

ZOU Jing; CHU Yaojuan; DU Qiuzheng; YUE Heying; WANG Xiaobao; DU Shuzhang

doi:10.6039/j.issn.1001-0408.2023.24.14

您当前的位置：

首页 >

文章列表页 >

Visual analysis of tyrosine kinase inhibitors in HER2 positive breast cancer

更新时间：2023-12-22

- Visual analysis of tyrosine kinase inhibitors in HER2 positive breast cancer
- ZHONGGUO YAOFANG Vol. 34, Issue 24, Pages: 3036-3041(2023)
- 作者机构：
  
  郑州大学第一附属医院药学部，郑州　450052
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.24.14
  CLC： R979.1;R737.9
- Published：30 December 2023，
  
  Received：17 July 2023，
  
  Revised：17 November 2023，
扫描看全文
邹婧,楚尧娟,杜秋争等.酪氨酸激酶抑制剂在HER2阳性乳腺癌中应用的可视化分析 ^Δ[J].中国药房,2023,34(24):3036-3041.

ZOU Jing,CHU Yaojuan,DU Qiuzheng,et al.Visual analysis of tyrosine kinase inhibitors in HER2 positive breast cancer[J].ZHONGGUO YAOFANG,2023,34(24):3036-3041.
邹婧,楚尧娟,杜秋争等.酪氨酸激酶抑制剂在HER2阳性乳腺癌中应用的可视化分析 ^Δ[J].中国药房,2023,34(24):3036-3041. DOI： 10.6039/j.issn.1001-0408.2023.24.14.

ZOU Jing,CHU Yaojuan,DU Qiuzheng,et al.Visual analysis of tyrosine kinase inhibitors in HER2 positive breast cancer[J].ZHONGGUO YAOFANG,2023,34(24):3036-3041. DOI： 10.6039/j.issn.1001-0408.2023.24.14.

摘要

目的

分析酪氨酸激酶抑制剂（TKIs）治疗人表皮生长因子受体2（HER2）阳性乳腺癌的研究现状、热点和发展趋势。

方法

在Web of Science核心合集数据库中检索TKIs治疗HER2阳性乳腺癌的相关文献，使用CiteSpace 6.1.R3软件对发文作者、国家/地区、机构、学科领域、期刊、关键词进行可视化分析。

结果

共纳入732篇文献，发文量呈逐年上升趋势，以美国发文最多（中心度0.10），我国发文量排第2位（中心度0.05）。发文量和被引频次最多的作者分别是澳大利亚圣文森特大学医院的Crown和美国加州大学洛杉矶分校的Slamon；发文量最多的机构是美国得克萨斯大学安德森癌症中心，最多的期刊是美国

Journal of Clinical Oncology

；研究热点主要集中在HER2阳性乳腺癌治疗药物、TKIs作用受体、TKIs作用机制、HER2阳性乳腺癌脑转移、TKIs临床研究5个方面；前沿领域和发展趋势主要为TKIs与其他药物或治疗手段联用以增强靶向性并降低毒副作用。

结论

TKIs治疗HER2阳性乳腺癌的研究受到国内外学者的重视。我国学者和研究团队未来需要加强合作交流，可从TKIs单用及联合用药治疗HER2阳性乳腺癌的疗效及安全性方面加强与其他国家的合作。

Abstract

OBJECTIVE

To analyze the research status， hotspot and development trend of tyrosine kinase inhibitors （TKIs） in the treatment of human epidermal growth factor receptor 2 （HER2） positive breast cancer.

METHODS

The literature related to TKIs in the treatment of HER2 positive breast cancer were searched from the Web of Science core collection database； the author， country/region， institution， subject field， journal and keywords was visualized by CiteSpace 6.1.R3 software.

RESULTS

A total of 732 pieces of literature were included， and the number of literature published showed an increasing trend year by year. The number of literature published in the United States was the largest （center degree 0.10）， and the number of literature published in China ranked second （center degree 0.05）. The most published and cited authors were Crown from St. Vincent’s University Hospital in Australia and Slamon from University of California， Los Angeles in the United States； the institution with the highest number of literature was the University of Texas MD Anderson Cancer Center， and the journal with the highest number of literature was

the Journal of Clinical Oncology

. The research mainly focused on five aspects： HER2 positive breast cancer treatment drugs， TKIs receptor， TKIs mechanism of action， HER2 positive breast cancer brain metastasis， and TKIs clinical trials. The main frontier areas and development trends were the combination of TKIs with other drugs or therapies to enhance targeting and reduce toxic side effects.

CONCLUSIONS

The study of TKIs in the treatment of HER2 positive breast cancer has attracted the attention of scholars at home and abroad. Chinese scholars and research teams need to strengthen cooperation and communication in the future， and cooperation with other countries should be strengthened in terms of the efficacy and safety of TKIs alone and combined with other drugs in the treatment of HER2 positive breast cancer.

关键词

酪氨酸激酶抑制剂人表皮生长因子受体-2阳性乳腺癌可视化分析

Keywords

human epidermal growth factor receptor-2 positive breast cancervisual analysis

references

CHOONG G M，CULLEN G D，O’SULLIVAN C C. Evolving standards of care and new challenges in the ma-nagement of HER2-positive breast cancer[J]. CA Cancer J Clin，2020，70（5）：355-374.

CAO W，CHEN H D，YU Y W，et al. Changing profiles of cancer burden worldwide and in China：a secondary analysis of the global cancer statistics 2020[J]. Chin Med J，2021，134（7）：783-791.

DESANTIS C E，MA J M，GAUDET M M，et al. Breast cancer statistics[J]. CA Cancer J Clin，2019，69（6）：438-451.

ROY V，PEREZ E A. Beyond trastuzumab：small mole-cule tyrosine kinase inhibitors in HER-2-positive breast cancer[J]. Oncologist，2009，14（11）：1061-1069．

CURIGLIANO G，MUELLER V，BORGES V，et al.Tucatinib vs placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases（HER2CLIMB）：final overall survival analysis[J]. Ann Oncol，2022，33（3）：321-329.

GEYER C E，FORSTER J，LINDQUIST D，et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer[J]. N Engl J Med，2006，355（26）：2733-2743.

NAHTA R，YUAN L X，ZHANG B，et al. Insulin-like growth factor-Ⅰ receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells[J]. Cancer Res，2005，65（23）：11118-11128.

CHEN Y，CHEN C M，LIU Z Y，et al. Methodological features of CiteSpace knowledge maps [J]. Sci Res，2015，33（2）：242-253.

ZENG Y，YU D L，TIAN W T，et al. Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer[J]. Curr Opin Oncol，2022，34（1）：54-65.

ZHUANG X L，WANG Z，FAN J S，et al. Structure-guided and phage-assisted evolution of a therapeutic anti-EGFR antibody to reverse acquired resistance[J]. Nat Commun，2022，13（1）：4431.

BAI X，SUN P Y，WANG X H，et al. Structure and dynamics of the EGFR/HER2 heterodimer[J]. Cell Discov，2023，9（1）：18.

CORTÉS J，FUMOLEAU P，BIANCHI G V，et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab：activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer[J]. J Clin Oncol，2012，30（14）：1594-1600.

CORTI C，ANTONARELLI G，CRISCITIELLO C，et al. Targeting brain metastases in breast cancer[J]. Cancer Treat Rev，2022，103：102324.

BAILLEUX C，EBERST L，BACHELOT T. Treatment strategies for breast cancer brain metastases[J]. Br J Cancer，2021，124（1）：142-155.

PARSAI S，MILLER J A，JULOORI A，et al. Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases[J]. J Neurosurg，2019，132（2）：503-511.

MORIKAWA A，STANCHINA E D，PENTSOVA E，et al. Phase Ⅰ study of intermittent high-dose lapatinib alterna-ting with capecitabine for HER2-positive breast cancer patients with central nervous system metastases[J]. Clin Cancer Res，2019，25（13）：3784-3792.

HURVITZ S，SINGH R，ADAMS B，et al. Phase Ⅰb/Ⅱ single-arm trial evaluating the combination of everolimus，lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases（TRIO-US B-09）[J]. Ther Adv Med Oncol，2018，10：1758835918807339.

MACPHERSON I R，SPILIOPOULOU P，RAFII S，et al. A phase Ⅰ/Ⅱ study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer[J]. Breast Cancer Res，2019，22（1）：1.

BRUFSKY A，ZULFIQAR M，PEGUERO J，et al. Abstract PD1-07：a phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer heavily pre-treated with HER2-targeted therapy[J]. Cancer Res，2021，81：PD1-7.

ZHANG J，MCANDREW N，YU W L，et al. Abstract P2-13-43：preclinical and early clinical safety and pharmacokinetics data of DZD1516，an BBB-penetrant selective HER2 inhibitor for the treatment of HER2 positive metastatic breast cancer[J]. Cancer Res，2022，82：P2-13.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Traditional Chinese medicine in the treatment of ulcerative colitis in 2013-2023： a bibliometric analysis

Artificial intelligence application in hospital pharmaceutical service： a bibliometric analysis

Visualization analysis of the therapy of recurrent high-grade gliomas based on CiteSpace

Visual analysis of the treatment of non-alcoholic fatty liver disease based on Web of Science

Analysis of research hotspots and trend of the clinical comprehensive evaluation of Chinese patent medicine in China

Related Author

DOU Danbo

HUANG Shiyun

GU Sizhen

ZENG Cheng

PENG Jun

HAO Chenye

FU Suqin

ZHAO Zhigang

Related Institution

Dept. of Traditional Medicine， Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Library & Information Center， Shanghai University of Medicine & Health Sciences

Dongming Community Health Service Center， Shanghai Pudong New Area

Dept. of Neurosurgery， Beijing Tiantan Hospital Affiliated to Capital Medical University

School of Pharmaceutical Sciences， Capital Medical University

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰